Invisible amniotic membrane mirror

Abstract

The utility model relates to an invisible amniotic membrane mirror which comprises an amniotic membrane area, a transition area and a landing area. The amnion area and the transition area are connected through a transparent connecting layer, and the transition area is connected to the landing area; the amnion area, the transition area and the landing area are coaxially arranged so that the amnion area, the transition area and the landing area can be coaxial with the optical axis of the pupil after being worn, the landing area can be supported on the sclera, and a cavity for containing tears can be defined by the transition area and the sclera edge. The ophthalmology eye patch has the advantages that the amniotic membrane area is located above the cornea to treat the eye, the landing area is attached to the sclera, stable supporting can be formed, the transition area connected with the landing area is located above the cornea sclera edge, safety of the cornea sclera edge is ensured, meanwhile, the landing area can be prevented from making contact with and stimulating the cornea, and therefore the wearing comfort is improved. And the three areas are mutually independent, thereby facilitating processing and mass production.

Description

Technical Field

[0001] This utility model relates to the field of contact lens technology, and in particular to a contact lens with an amniotic membrane. Background Technology

[0002] The amnion is the innermost layer of the placenta, containing substances necessary for the growth of conjunctival cells and corneal epithelial cells. Its surface is smooth, and it contains no blood vessels, nerves, or lymphatics. It possesses a certain degree of elasticity and is approximately 0.02–0.5 mm thick. It is composed of the epithelial layer, basement membrane, compact layer, fibroblast layer, and spongy layer. The amnion's structure is similar to that of the human conjunctiva, containing ocular surface epithelial cells, including substances necessary for the growth of conjunctival and corneal epithelial cells. It plays a role in promoting epithelial repair, inhibiting scar formation, suppressing corneal neovascularization, and inhibiting immune responses. Therefore, the amnion has been widely used in the treatment of ocular surface diseases.

[0003] Currently, CN112155845A discloses a conformal amniotic lens, including a ring-shaped conformal part, on which the amniotic membrane is fixed. The lower surface of the conformal part is attached to the ocular surface, and the conformal part moves in sync with the eyeball when it is attached to the ocular surface. This allows the amniotic lens to remain firmly attached to the ocular surface and move in sync with the eyeball during prolonged wear, ensuring the amniotic membrane on the lens remains in the treatment position, thus solving the problem of lens displacement caused by the inability of previous amniotic lenses to move in sync with the eyeball. Structurally, the amniotic membrane is fixed to the conformal part, and the lower surface of the conformal part adheres to the sclera. However, due to the shapes of the cornea, limbus, and sclera, it does not perfectly fit the shape of the ocular surface, resulting in a less than ideal wearing experience. Utility Model Content

[0004] (1) Technical issues to be resolved

[0005] In view of the above-mentioned shortcomings and deficiencies of the prior art, the present invention provides a concealed amniotic lens, which solves the technical problem of poor wearing experience of the prior art.

[0006] (2) Technical solution

[0007] In order to achieve the above-mentioned purpose, the main technical solutions adopted by this utility model include:

[0008] This invention provides a concealed amniotic lens, comprising an amniotic region, a transition region, and a landing region; the amniotic region and the transition region are connected by a transparent connecting layer, and the transition region is connected to the landing region; the amniotic region, the transition region, and the landing region are coaxially arranged so that they can be coaxial with the optical axis of the pupil after being worn; the landing region can be supported on the sclera; and the transition region can be enclosed with the limbus to form a cavity for accommodating tears.

[0009] Optionally, the inner side of the connecting layer has a connecting groove that fits the inner side of the amniotic membrane area, and a drug layer is provided in the connecting groove so that the side of the drug layer can be exposed in the cavity.

[0010] Optionally, the connecting layer is formed by curing a biocompatible adhesive.

[0011] Optionally, the biocompatible adhesive is a biohydrogel.

[0012] Optionally, the thickness of the connecting layer is 50–80 μm.

[0013] Optionally, the height of the cavity is 100–250 μm.

[0014] Optionally, the amniotic region is spherical and its vertical projection is circular, the transition region is aspherical and its vertical projection is annular, and the landing region is spherical and its vertical projection is annular.

[0015] Optionally, the diameter of the vertical projection of the amniotic region is 4–11 mm; the outer diameter of the vertical projection of the transition region is 10–13 mm; and the outer diameter of the vertical projection of the landing region is 13–17 mm.

[0016] Optionally, the transition zone and the landing zone are made of an oxygen-permeable material.

[0017] (3) Beneficial effects

[0018] The beneficial effects of the utility model are:

[0019] This invention provides a hidden amniotic lens. When worn, the amniotic zone is positioned in front of the cornea to treat the eye, while the landing zone adheres to the sclera, providing stable support. The transition zone connecting the landing zone is located in front of the limbus, ensuring the safety of the limbus and preventing the landing zone from contacting and irritating the cornea, thus improving wearing comfort. It is also suitable for people with corneal diseases. A transparent connecting layer connects the amniotic zone and the transition zone, ensuring a stable connection without obstructing vision. The transition zone and the limbus together form a cavity to accommodate tear fluid, providing a continuous water bath effect for patients with dry eye disease and alleviating discomfort. The design features independent amniotic, transition, and landing zones for easy mass production. Attached Figure Description

[0020] Figure 1 This is a schematic diagram of the structure of the hidden amnioscope in a specific embodiment of the present invention.

[0021] Figure 2 This is a top view schematic diagram of the hidden amnioscope in a specific embodiment of the present invention.

[0022] Figure 3 This is a schematic diagram of the structure of the invisible amniotic lens during wear in a specific embodiment of the present invention;

[0023] Figure 4 for Figure 3 Enlarged view of point A in the middle.

[0024] [Explanation of Labels in the Attached Image]

[0025] 1: Amniotic zone; 2: Transition zone; 3: Landing zone; 4: Connecting layer; 5: Drug layer; 6: Cornea; 7: Limb of the cornea and sclera; 8: Sclera. Detailed Implementation

[0026] To better understand the above technical solutions, exemplary embodiments of the present invention will be described in more detail below with reference to the accompanying drawings. Although exemplary embodiments of the present invention are shown in the drawings, it should be understood that the present invention can be implemented in various forms and should not be limited to the embodiments set forth herein. Rather, these embodiments are provided so that the present invention can be understood more clearly and thoroughly, and that the scope of the present invention can be fully conveyed to those skilled in the art.

[0027] like Figure 1 and Figure 2 As shown, this embodiment provides a concealed amniotic lens, including an amniotic region 1, a transition region 2, and a landing region 3. The amniotic region 1 and the transition region 2 are connected by a transparent connecting layer 4, and the transition region 2 is connected to the landing region 3. The amniotic region 1, the transition region 2, and the landing region 3 are coaxially arranged so that they can be coaxial with the optical axis of the pupil after being worn. The landing region 3 can be supported by the sclera 8, and the transition region 2 can be enclosed with the limbus 7 to form a cavity for accommodating tears. Specifically, the height of the cavity is 100-250 μm. In this specific embodiment, the transition region 2 and the landing region 3 are made of an ultra-permeable material. Preferably, the transition region 2 and the landing region 3 are made of Boston XO2 material with an oxygen permeability coefficient DK value of 141, achieving ultra-high oxygen permeability while ensuring good elastic modulus, hardness, and wettability of the material.

[0028] Specifically, after wearing, the amniotic membrane area 1 is positioned above the cornea 6 to treat the eye, while the landing area 3 adheres to the sclera 8, providing stable support. The transition area 2, connecting the landing area 3, is located in front of the limbus 7, ensuring the safety of the limbus 7 and preventing the landing area 3 from contacting and irritating the cornea 6, thus improving wearing comfort and making it suitable for people with corneal diseases. A transparent connecting layer 4 connects the amniotic membrane area 1 and the transition area 2, ensuring a stable connection without affecting vision. The transition area 2 and the limbus 7 together form a cavity to accommodate tear fluid, providing a continuous water bath effect for dry eye patients and alleviating their discomfort. The design features independent areas for the amniotic membrane area 1, transition area 2, and landing area 3 for easy mass production.

[0029] Furthermore, in this specific embodiment, the connecting layer 4 is formed by curing a biocompatible adhesive, and its thickness is 50-80 μm. This ensures the connection between the amniotic membrane region 1 and the transition region 2 without affecting the usability of the amniotic membrane region 1 and the transition region 2. The biocompatible adhesive is preferably a bio-hydrogel, a bio-adhesive commonly used in the biomedical field. Its curing process is conventional light curing or cooling curing. It should be noted that this is only a preferred option; other biocompatible adhesives can achieve the same effect.

[0030] Furthermore, as shown in the figure, the inner side of the connecting layer 4 has a connecting groove that conforms to the inner side of the amniotic membrane region 1. A drug layer 5 is disposed within the connecting groove, allowing the sides of the drug layer 5 to be exposed within the cavity. The drug layer 5 is formed by solidifying a drug that relieves eye fatigue. It is compatible with tears, forming a medicinal solution within the cavity to relieve eye fatigue.

[0031] Furthermore, as shown in the figure, the amniotic region 1 is spherical with a circular vertical projection, the transition region 2 is aspherical with a ring-shaped vertical projection, and the landing region 3 is spherical with a ring-shaped vertical projection. The diameter of the vertical projection of the amniotic region 1 is 4–11 mm; the outer diameter of the vertical projection of the transition region 2 is 10–13 mm; and the outer diameter of the vertical projection of the landing region 3 is 13–17 mm, making it suitable for most people.

[0032] In this specific embodiment, when the user wears the contact lens, the landing area 3 of the contact lens fits and supports the user's sclera 8, and the transition area 2 and the user's limbus 7 enclose a cavity to accommodate tears. The tears accumulate in the cavity, and the drug layer 5 blends with the tears in the cavity to form a medicated solution that acts on the eye, relieving eye fatigue and improving the wearing experience.

[0033] In the description of this utility model, it should be understood that the terms "first" and "second" are used for descriptive purposes only and should not be construed as indicating or implying relative importance or implicitly specifying the number of indicated technical features. Therefore, a feature defined as "first" or "second" may explicitly or implicitly include one or more of that feature. In the description of this utility model, "a plurality of" means two or more, unless otherwise explicitly specified.

[0034] In this utility model, unless otherwise explicitly specified and limited, the terms "installation," "connection," "joining," and "fixing," etc., should be interpreted broadly. For example, they can refer to a fixed connection, a detachable connection, or an integral part; they can refer to a mechanical connection or an electrical connection; they can refer to a direct connection or an indirect connection through an intermediate medium; they can refer to the internal communication of two components or the interaction between two components. For those skilled in the art, the specific meaning of the above terms in this utility model can be understood according to the specific circumstances.

[0035] In this utility model, unless otherwise explicitly specified and limited, "above" or "below" the second feature can mean that the first feature is in direct contact with the second feature, or that the first feature is in indirect contact with the second feature through an intermediate medium. Furthermore, "above," "on top of," and "over" the second feature can mean that the first feature is directly above or diagonally above the second feature, or simply indicates that the first feature is at a higher horizontal level than the second feature. "Below," "below," and "beneath" the second feature can mean that the first feature is directly below or diagonally below the second feature, or simply indicates that the first feature is at a lower horizontal level than the second feature.

[0036] In the description of this specification, the terms "one embodiment," "some embodiments," "embodiment," "example," "specific example," or "some examples," etc., refer to specific features, structures, materials, or characteristics described in connection with that embodiment or example, which are included in at least one embodiment or example of the present invention. In this specification, the illustrative expressions of the above terms do not necessarily refer to the same embodiment or example. Furthermore, the specific features, structures, materials, or characteristics described may be combined in any suitable manner in one or more embodiments or examples. Moreover, without contradiction, those skilled in the art can combine and integrate the different embodiments or examples described in this specification, as well as the features of different embodiments or examples.

[0037] Although embodiments of the present invention have been shown and described above, it is understood that the above embodiments are exemplary and should not be construed as limiting the present invention. Those skilled in the art can make modifications, alterations, substitutions and variations to the above embodiments within the scope of the present invention.

Claims

1. A hidden amniocentesis, characterized in that, It includes the amniotic region (1), the transition region (2), and the landing region (3); The amniotic region (1) and the transition region (2) are connected by a transparent connecting layer (4), and the transition region (2) is connected to the landing region (3); The amniotic region (1), the transition region (2) and the landing region (3) are coaxially arranged so that they can be coaxial with the optical axis of the pupil after being worn. The landing region (3) can be supported by the sclera (8), and the transition region (2) can be enclosed with the limbus (7) to form a cavity for containing tears.

2. The invisible amniocentesis as described in claim 1, characterized in that, The inner side of the connecting layer (4) has a connecting groove that fits the inner side of the amniotic membrane region (1), and a drug layer (5) is provided in the connecting groove so that the side of the drug layer (5) can be exposed in the cavity.

3. The invisible amniocentesis as described in claim 1, characterized in that, The connecting layer (4) is formed by curing a biocompatible adhesive.

4. The invisible amniocentesis as described in claim 3, characterized in that, The biocompatible adhesive is a biohydrogel.

5. The invisible amniocentesis as described in claim 1, characterized in that, The thickness of the connecting layer (4) is 50-80 μm.

6. The invisible amniocentesis as described in claim 1, characterized in that, The height of the cavity is 100–250 μm.

7. The invisible amniocentesis as described in claim 1, characterized in that, The amniotic region (1) is spherical and its vertical projection is circular, the transition region (2) is aspherical and its vertical projection is annular, and the landing region (3) is spherical and its vertical projection is annular.

8. The invisible amniocentesis as described in claim 7, characterized in that, The diameter of the vertical projection of the amniotic region (1) is 4 to 11 mm; The outer diameter of the vertical projection of the transition zone (2) is 10-13 mm; The outer diameter of the vertical projection of the landing area (3) is 13-17 mm.

9. The invisible amniocentesis as described in claim 1, characterized in that, The transition zone (2) and the landing zone (3) are made of ultra-permeable oxygen material.

Images